The Tissue/Pathology Core is a central facility providing support for the Investigators of The University of Michigan SCOR proposal. This Core will process both human or rodent lung tissue for the purpose of tissue protein and mRNA analysis, light microscopy, image analysis (qualitative and quantitative measurements) of microscopic images, and isolation, passage, and characterization of human pulmonary or dermal fibroblasts. Human bronchoalveolar lavage (BAL) fluid and cells will be processed for protein and mRNA analysis, levels of N-terminal type III procollagen peptide by immunoassay, and total cell count and differential. In addition, this core will generate a Pulmonary Pathology Tissue Score for each human lung specimen obtained from both patients with interstitial lung disease and control (patients undergoing thoracic surgery for reasons other than interstitial lung disease). These services will be used by all the projects of the SCOR proposal. Projects I, II, and III will extensively use isolated pulmonary (Projects I, II, and III) and dermal (Project II) fibroblasts from normal, IPF, and sarcoidosis patients. Projects I, IV, and V will require processing of bleomycin- induced rodent pulmonary fibrosis or normal lung tissue for further analysis. The levels of total protein, albumin, and N-terminal type III procollagen peptide in the BAL fluid will be used by both the Clinical Core and basic science projects I, II, and III to correlate these levels with levels of angiogenic or angiostatic CXC chemokines, metabolites of arachidonate, and profiles of Th1 and Th2 cytokines, respectively. We believe that we have assembled the appropriate personnel with the needed expertise to design and conduct the appropriate studies which will provide the Investigators of this SCOR project with reliable and reproducible specimens.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Specialized Center (P50)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Schmidt, S L; Nambiar, A M; Tayob, N et al. (2011) Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 38:176-83
Trujillo, Glenda; Meneghin, Alessia; Flaherty, Kevin R et al. (2010) TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med 2:57ra82
Fell, Charlene D; Martinez, Fernando J; Liu, Lyrica X et al. (2010) Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 181:832-7
Huang, Steven K; White, Eric S; Wettlaufer, Scott H et al. (2009) Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J 23:4317-26
Fell, Charlene D; Liu, Lyrica Xiaohong; Motika, Caroline et al. (2009) The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179:402-7
White, Kimberly E; Ding, Qiang; Moore, Bethany B et al. (2008) Prostaglandin E2 mediates IL-1beta-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors. J Immunol 180:637-46
Huang, Steven K; Peters-Golden, Marc (2008) Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time? Chest 133:1442-50
Han, M K; Murray, S; Fell, C D et al. (2008) Sex differences in physiological progression of idiopathic pulmonary fibrosis. Eur Respir J 31:1183-8
Muro, Andres F; Moretti, Federico A; Moore, Bethany B et al. (2008) An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med 177:638-45
Huang, Steven K; Wettlaufer, Scott H; Hogaboam, Cory M et al. (2008) Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia. Am J Respir Crit Care Med 177:66-74

Showing the most recent 10 out of 96 publications